Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06406400 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT06406400 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 15 participants.
The verdict
NCT06406400, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of the study is to assess drug-drug interaction (DDI) and safety of AZD4041 and itraconazole in healthy participants (Part 1), and to assess efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD404 when administered with buprenorphine/buprenorphine + naloxone in participants with moderate to severe opioid use disorder (OUD)
Interventions
- DRUG Hydromorphone
- DRUG Itraconazole
- DRUG Buprenorphine
- DRUG AZD4041
- DRUG Buprenorphine / Naloxone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-05-13 |
| Est. Completion | 2024-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06406400
The ClinicalTrials.gov registry entry for NCT06406400 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Hydromorphone is the first listed.
NCT06406400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06406400 about?
NCT06406400 is a clinical study titled "Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).". The purpose of the study is to assess drug-drug interaction (DDI) and safety of AZD4041 and itraconazole in healthy participants (Part 1), and to assess efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD404 when administered with buprenorphine/buprenorphine + naloxone in partic...
What is the current status of trial NCT06406400?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2024-05-13. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT06406400?
The interventions under investigation include: Hydromorphone (DRUG), Itraconazole (DRUG), Buprenorphine (DRUG), AZD4041 (DRUG), Buprenorphine / Naloxone (DRUG).
Who is sponsoring clinical trial NCT06406400?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.